Lupin Launches Lapatinib Tablets

▴ lupin-launches-lapatinib-tablets
Lupin announced today the launch of Lapatinib Tablets, 250 mg, after Lupin’s alliance partner Natco Pharma Ltd received final approval for its ANDA from the USFDA

Pharma major Lupin Limited (Lupin) announced today the launch of Lapatinib Tablets, 250 mg, after Lupin’s alliance partner Natco Pharma Ltd received final approval for its ANDA from the United States Food and Drug Administration (U.S. FDA).

Lapatinib Tablets, 250 mg, are the generic equivalent of Tykerb Tablets, 250 mg, of Novartis Pharmaceutical Corporation, and are indicated in combination with:

Capecitabine for the treatment of patients with advanced or metastatic breast cancer whose tumors overexpress human epidermal growth factor receptor 2 (HER2), and who have received prior therapy including an anthracycline, a taxane, and trastuzumab Letrozole for the treatment of postmenopausal women with hormone-receptor-positive metastatic breast cancer that overexpresses the HER2 receptor, for whom hormonal therapy is indicated

Lapatinib Tablets (RLD: Tykerb®) had annual sales of approximately USD 61 million in the U.S. (IQVIA MAT June 2020)

Tags : #LatestPharmaNewsSep30 #LatestLupinNewsSep30 #LapatinibTablets #natcopharma #postmenopausalwomen

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Teenagers Are Losing Friends While Chasing Perfection: Here’s WhyMarch 13, 2025
Your Desk Job is Destroying Your Mind: Here’s How to Fight BackMarch 13, 2025
Wow! Momo Disrupts FMCG Cup Noodles Market with 'Desi-Asian Flavours' – A First in IndiaMarch 13, 2025
How India’s Kidney Health Crisis is Growing UnnoticedMarch 13, 2025
Stuck Between the Snooze Button and the Hustle: Entrepreneurs Struggle to Get Quality SleepMarch 13, 2025
Can Coffee Keep You Steady on Your Feet? New Study Reveals the TruthMarch 13, 2025
NephroPlus Sets Guinness World Record & India Book of Records Title for Largest Kidney Health Screening DriveMarch 12, 2025
India Choosing to Eat Healthy; Order Volumes Up by 60% for Nutritional ProductsMarch 12, 2025
Amrita students win first prize at DecodeX 2025 hackathonMarch 12, 2025
Why Millions Are Losing Their Sight to Glaucoma And How You Can Prevent ItMarch 12, 2025
Çelebi India Ranks 3rd Worldwide in Ground Handling Performance for Turkish CargoMarch 12, 2025
Advancing Road Safety Through Clear Vision: VARS 4.0 Sets Bold AgendaMarch 12, 2025
The Deadly Cost of the “Perfect Body”: When Diet Trends Turn FatalMarch 12, 2025
Lighthouse Canton’s LC GenInnov Global Innovation Fund Secures Investment from Kotak Mahindra Asset ManagementMarch 11, 2025
TTK Prestige Revolutionizes Cooking with Innovative AirFlip Two-in-One Air Fryer and GrillMarch 11, 2025
Rewriting Immunology: The Discovery That Could Replace Traditional AntibioticsMarch 11, 2025
Is Your Cooking Oil Poisoning You? The Truth About Seed OilsMarch 11, 2025
Think Before You Bite: How Fatty Foods Can Trigger Brain Damage in Just 3 DaysMarch 11, 2025
Ditch the Pills: The Secret to Beating Insomnia is in Your WorkoutMarch 11, 2025
The University of Tasmania invites applications for Master of Public HealthMarch 11, 2025